Establishment Labs Holdings Inc. (ESTA) · Oct 29, 2026 · Earnings
Mixed results — Revenue $72.0M vs ~$66.8M consensus; GAAP EPS $(0.35) vs ~$(0.26)
Establishment Labs’ Q3 earnings show accelerating revenue, operating leverage and first-ever positive quarterly free cash flow, offset by a GAAP EPS miss.
Establishment Labs is scaling a breast-aesthetics and reconstruction device platform, with U.S. sales and minimally invasive products becoming the main growth vectors. Its prior quarter had already raised fiscal 2026 revenue guidance and pointed to a second-half cash-flow inflection, so this release confirms a trajectory that was partly established rather than introducing an entirely new story.
Revenue materially cleared the market’s bar. Q3 revenue reached $72.0 million, 33.9% above last year and roughly 7.8% above the published consensus of about $66.8 million. U.S. revenue grew 119%, while minimally invasive revenue more than doubled to approximately $9 million, showing that the intended commercial expansion is translating into reported sales.
The operating model is improving faster than the GAAP bottom line. Adjusted EBITDA rose to $6.4 million from $1.2 million a year ago, and adjusted operating expenses fell to 68.8% of revenue from 77.6%. Adjusted gross margin also improved to 70.8%, although GAAP gross margin declined to 69.1% because of $1.3 million of restructuring-related inventory charges.
Cash generation is the quarter’s most meaningful business milestone. The company produced $7.7 million of operating cash flow and $5.1 million of free cash flow, its first positive quarterly free-cash-flow result. That is a clear advance from the prior-year cash burn, but nine-month free cash flow remains negative at $21.4 million, so the turnaround is not yet proven over a full year.
The earnings miss keeps the result from being a clean beat. GAAP loss per share was $(0.35), wider than the roughly $(0.26) consensus loss, despite the revenue outperformance and better operating leverage. Interest expense of $6.8 million remains a meaningful drag, while net debt is substantial relative to the $75.8 million cash balance; the balance sheet therefore still depends on continued growth and cash-flow execution. The release also introduced a fiscal 2027 target of 25% growth and positive cash flow, but that is management’s outlook rather than a benchmark with an established consensus. 〔0〕
| Metric | Q3 2026 | Q3 2025 | Consensus / comparison |
|---|---|---|---|
| Revenue (Financial Statements) | $72.0M (+33.9%) | $53.8M | ~$66.8M |
| GAAP EPS (Financial Statements) | $(0.35) | $(0.38) | ~$(0.26) |
| Adjusted EBITDA (Adjusted EBITDA reconciliation) | $6.4M | $1.2M | |
| Adjusted gross margin (Adjusted gross profit reconciliation) | 70.8% | 70.1% | |
| Free cash flow (Free cash flow reconciliation) | $5.1M | $(13.2M) | |
| Cash and equivalents (Balance Sheet) | $75.8M | $75.6M at Dec. 31 | |
| FY2027 growth guide (Press release) | 25% |
Bottom line: This was a genuine operating improvement, led by revenue, cost leverage and the first positive quarterly cash flow. But the GAAP EPS miss and still-levered balance sheet make it a mixed earnings read rather than a clean upside surprise.
Q4 report and FY2027 outlook update
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!